ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 1080 • ACR Convergence 2020

    Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America

    Antonia Maria Valenzuela Vergara1, Magdalena Torres1 and Alejandro Deves1, 1Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterized by muscle inflammation and internal organ involvement. The Bohan & Peter (B&P) criteria…
  • Abstract Number: 044 • 2020 Pediatric Rheumatology Symposium

    Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network

    Sonia Savani1, Natasha Ruth 2, Paul Nietert 1, Gabrielle Morgan 3, Mileka Gilbert 1 and Lauren Pachman 4, 1Medical University of South Carolina, Charleston, South Carolina, 2Medical University South Carolina, Charleston, South Carolina, 3Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois, 4Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, 303 E Superior, Chicago

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic autoimmune disease characterized by vasculopathy and rash. The Bohan-Peter criteria for dermatomyositis are not ideal. There is…
  • Abstract Number: 405 • 2019 ACR/ARP Annual Meeting

    Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature

    Mohammad Ryadh Pokeerbux1, Luc Dauchet 2, Benjamin Lopez 3, Hélène Maillard 1, Sandrine Morell-Dubois 1, Eric Auxenfants 4 and Eric Hachulla 5, 1Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, 2Department of Epidemiology, CHU Lille, University of Lille, Lille, France, 3Institute of Immunology, CHU Lille, University of Lille, Lille, France, 4Department of Internal Medicine, Roubaix Hospital, Roubaix, France, 5Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France

    Background/Purpose: Anti-MDA5 dermatomyositis is characterized by little or no muscle involvement, distinct cutaneous features and an increased risk of severe interstitial lung disease (ILD) with…
  • Abstract Number: 2843 • 2019 ACR/ARP Annual Meeting

    Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects

    Victoria Werth1, David Pearson 2, Joyce Okawa 2, Rui Feng 3, Josef Concha 2, Basil Patel 2, Emily Hejazi 2, Scott Constantine 4, Nancy Dgetluck 4 and Barbara White 4, 1Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 2Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, 4Corbus Pharmaceuticals, Norwood, MA

    Background/Purpose: Lenabasum is a rationally-designed preferential cannabinoid receptor type 2 agonist that activates resolution of innate immune responses to reduce tissue inflammation and fibrotic processes.…
  • Abstract Number: 412 • 2019 ACR/ARP Annual Meeting

    Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease

    Takashi Matsushita1, Tadahiro Kobayashi 1, Miyu Kano 1, Yasuhito Hamaguchi 1 and Kazuhiko Takehara 2, 1Kanazawa University, Kanazawa, Japan, 2Department of Dermatology, Kanazawa University, Kanazawa, Japan

    Background/Purpose: Patients with dermatomyositis (DM) frequently have myositis-specific autoantibodies (MSAs), which are closely associated with different clinical features. Patients with anti-aminoacyl-tRNA synthetase (ARS) antibody (Ab)…
  • Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting

    New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody

    Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Shinichi Nogi 4, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 5, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, 5Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

    Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
  • Abstract Number: 1276 • 2019 ACR/ARP Annual Meeting

    Myositis Specific Antibodies and Clinical Features in Patients from Argentina

    Amelia Granel1, Maria de Los Angeles Gargiulo 2, Ana Carolina Marcos 3, Ramiro Gomez 4, Andrea Braillard Poccard 5, Carolina Costi 6, Mercedes Garcia 7, Malena Viola 8, Maria de la Vega 9, Belen Barrios 10, Silvia Papasidero 11, Boris Kisluk 12, Guillermo Berbotto 12, Mariana Aciar 13, María Crespo Espíndola 14, Mariano Rivero 15, Maria N Lojo 16, Yessica Ponce Delgado 17, Oscar Rillo 18, Ramiro Puerta 19, Isabel Pineda 20, Dafne Capelusnik 21, Roberto Movia 22, Darío Scublinsky 23, Maria Alicia Lazaro 24 and Graciela Gómez 25, 1Hospital San Roque,Gonnet,La Plata,Buenos Aires.Argentina, La Plata, Buenos Aires, Argentina, 2Instituto de Investigaciones Médicas,Alfredo Lanari.Universidad de Buenos Aires.Argentina, Ciudad de Buenos Aires, Argentina, 3Hospital San Roque,Gonnet,La Plata,Buenos Aires.Argentina, Gonnet, Argentina, 4Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 5Hospital de Clínicas José de San Martin, Buenos Aires, Buenos Aires, Argentina, 6Hospital General “San Martín” de la Plata, La Plata, Buenos Aires, Argentina, 7Hospital San Martín, La Plata, Argentina, 8Centro Reumatologia DOM, Buenos Aires, Buenos Aires, Argentina, 9CEIM Investigaciones Medicas, Buenos Aires, Argentina, 10Hospital Enrique Tornu,Ciudad de Buenos Aires.Argentina, Ciudad de Buenos Aires, Argentina, 11Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 12Hospital Escuela Eva Perón.Granadero Baigorria,Santa Fe.Argentina, Granadero Baigorria, Argentina, 13Hospital Ntro Señor del Milagro, Salta.Argentina., Salta, Argentina, 14Hospital Señor del Milagro, Salta, Salta, Argentina, 15Hospital Británico, Buenos Aires, Buenos Aires, Argentina, 16Hospital Rossi,La Plata.Argentina, La Plata, Argentina, 17Hospital Pirovano.Ciudad de Buenos Aires. Argentina, Ciudad de Buenos Aires, Argentina, 18Hospital Pirovano, Buenos Aires, 19Hospital Houssay.Vicente Lopez,Buenos Aires.Argentina., Vicente Lopez, Argentina, 20Consultorios Externos Venado Tuerto.Santa Fe.Argentina., Venado Tuerto, Argentina, 21Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, 22Hospital Evita.Lanus.Pcia Buenos Aires. Argentina, Lanus, Argentina, 23Centros Médicos Ambulatorios SMG, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 24Consultorio Particular, San Isidro, Argentina, 25Instituto de Investigaciones Médicas,Alfredo Lanari.Universidad de Buenos Aires.Argentina., Buenos Aires, Argentina

    Background/Purpose: To know the frequency of myositis specific antibodies (MSAs) and myositis associated antibodies( MAAs) and their relation with clinical features in patients with idiopathic…
  • Abstract Number: 1278 • 2019 ACR/ARP Annual Meeting

    Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States

    Patompong Ungprasert1, Wisit Cheungpasitporn 2, Charat Thongprayoon 3, Karn Wijarnpreecha 4 and Paul Kroner 5, 1Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, 2University of Mississippi Medical Center, Jackson, MS, 3Mayo Clinic Rochester, Rochester, MN, 4Mayo Clinic Florida, Jacksonville, FL, 5Mayo Clinic Florida, Jacksonville

    Background/Purpose: Dermatomyositis (DM) and polymyositis (PM), collectively known as idiopathic inflammatory myositis (IIM), are autoimmune disorders characterized by inflammation of skeletal muscle, especially in the…
  • Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting

    Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management

    Alain Sánchez-Rodríguez1, Citlallyc Josefina Gómez-Ruiz 2, Abril Montes-Yanes 2 and Gabriel Medrano-Ramírez 2, 1Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, 2Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico

    Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…
  • Abstract Number: 1280 • 2019 ACR/ARP Annual Meeting

    JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis

    Océane Landon-Cardinal1, Perrine Guillaume-Jugnot 2, Lois Bolko 2, Ségolène Toquet 2, Aude Rigolet 2, Baptiste Hervier 3, Nicolas Champtiaux 2, Mathieu VAUTIER 4, Olivier Benveniste 5 and Yves Allenbach 5, 1Centre Hospitalier de l'Université de Montréal, Montréal, Canada, 2Pitié-Salpêtrière University Hospital, Paris, France, 3Hopital Pitie-Salpetriere, Paris, France, 4Paris - Pitié salpétrière, Paris, France, 5Sorbonne Université, Paris, France

    Background/Purpose: We previously observed in vitro that IFN-I reproduces dermatomyositis (DM) pathological findings, that pathogenic effects may be prevented in vitro by JAK inhibitor (JAKinh) therapy and an improvement…
  • Abstract Number: 1285 • 2019 ACR/ARP Annual Meeting

    Changes in Nail-fold Capillary Abnormalities, and Serum FGF and VEGF Levels in Dermatomyositis Patients with anti-MDA5 Antibody During the Clinical Course

    Yasuhito Hamaguchi1, Takashi Matsushita 1, Naoki Mugii 2 and Kazuhiko Takehara 1, 1Department of Dermatology, Kanazawa University, Kanazawa, Japan, 2Kanazawa University Hospital, Kanazawa, Japan

    Background/Purpose: Capillary abnormalities in the nail-fold are a characteristic finding of microangiopathy in autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis. A previous study…
  • Abstract Number: 1290 • 2019 ACR/ARP Annual Meeting

    Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy

    Iago Pinal-Fernandez1, Maria Casal-Dominguez 1, Assia Derfoul 1, Katherine Pak 1, Paul Plotz 1, Frederick W. Miller 2, Jose C Milisenda 3, Josep M Grau-Junyent 3, Albert Selva-O'Callaghan 4, Julie Paik 5, Jemima Albayda 6, Lisa Christopher-Stine 7, Thomas E Lloyd 5, Andrea M Corse 5 and Andrew L Mammen 1, 1National Institutes of Health, Bethesda, 2NIEHS, NIH, Bethesda, MD, 3Clinic Hospital, Barcelona, 4Department of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Barcelona, Spain, Barcelona, 5Johns Hopkins, Baltimore, 6Johns Hopkins University, Baltimore, MD, 7Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Activation of the type 1 interferon (IFN1) pathway is a prominent feature of dermatomyositis (DM) muscle and may play a role in the pathogenesis…
  • Abstract Number: 1296 • 2019 ACR/ARP Annual Meeting

    Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema

    Majid Zeidi1, Kristen Chen 1, Basil Patel 2, Rachel Lim 3 and Victoria Werth 1, 1Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 2Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 3Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA, Philadelphia

    Background/Purpose: Dermatomyositis (DM) is conventionally characterized by interface dermatitis (ID) on skin histopathology. A subset of patients with clinically diagnosed DM have skin biopsies showing…
  • Abstract Number: 1866 • 2019 ACR/ARP Annual Meeting

    Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues

    Jessica Neely1, Dmitry Rychkov 1, Manish Paranjpe 1, Michael Waterfield 2, Susan Kim 1 and Marina Sirota 2, 1University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco

    Background/Purpose: Dermatomyositis (DM) is a complex immune-mediated disease resulting in muscle and skin inflammation.  Prior studies of gene expression in DM have revealed a type…
  • Abstract Number: 1869 • 2019 ACR/ARP Annual Meeting

    Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders

    Kristen Chen1, Majid Zeidi 1, Maria Wysocka 2, Nithin Reddy 1, Arvin Jadoo 1, Muhammad Bashir 1, Sarah Ahmed 2, Basil Patel 2, Kevin Zhang 2, Barbara White 3 and Victoria Werth 1, 1Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 2Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 3Corbus Pharmaceuticals, Norwood, MA

    Background/Purpose: Dermatomyositis (DM) is an autoimmune disease affecting the skin, skeletal muscle, lungs, and/or other organs. While the pathogenesis remains poorly understood, it is thought…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology